Concentrations of Formoterol in Blood and Urine
Study Details
Study Description
Brief Summary
The purpose of the study is to assess the blood and urine concentrations of inhaled formoterol.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 4 |
Detailed Description
The purpose of the study is to assess the serum and urine concentrations after inhalation of 18 microgram formoterol as one dose.
Furthermore to investigate the serum and urine concentrations of inhaled formoterol and evaluate the difference between three groups: healthy men, male asthmatic subjects and male elite athletes with asthma.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Other: Healthty 10 healthy men |
Drug: inhaled formoterol
Inhalation of 18 microgram formoterol as one dose. Oxis Turbohaler 9 microg/dose, MA no. 30072.
Other Names:
|
Other: Asthmatics 10 male asthmatic subjects |
Drug: inhaled formoterol
Inhalation of 18 microgram formoterol as one dose. Oxis Turbohaler 9 microg/dose, MA no. 30072.
Other Names:
|
Other: Elite asthmatics 10 male elite athletes with asthma |
Drug: inhaled formoterol
Inhalation of 18 microgram formoterol as one dose. Oxis Turbohaler 9 microg/dose, MA no. 30072.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Serum and urine concentrations of formoterol [baseline, 4, 8, and 12 hours after medicine administration]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Physician-diagnosed asthma with positive reversibility or challenge test.
-
Informed consent.
-
Age between 18-45 years.
-
Sex: male.
-
Asthma classified as mild to moderate according to GINA guidelines.
-
Used beta-2-agonist in minimum 12 months.
Exclusion Criteria:
-
Smokers or ex-smokers with a smoking history of 10 pack years or more.
-
Respiratory tract infections within the last 2 weeks prior to study day.
-
Subjects with other chronic diseases than asthma and allergy.
-
Allergy towards the study medicine.
-
Use of beta-2-agonist 10 days prior to study day.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Bispebjerg Hospital, Respiratory Research Unit | Kobenhavn NV | Denmark | DK-2400 |
Sponsors and Collaborators
- Bispebjerg Hospital
- Hormone Laboratory, Aker University Hospital, Oslo, Norway
Investigators
- Principal Investigator: Jimmi Elers, MD, Bispebjerg Hospital, Respiratory Research Unit
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- FOR2009JE
- EudraCT number 2009-012039-14